Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin as Add-on to Closed-loop Control in T1D
NCT02987738Phase 1Completed
- Sponsor
- Kinderkrankenhaus Auf der Bult
- Start
- Feb 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Dapagliflozin Sequence with Placebo Sequence (2 arms). Primary endpoint: Time in Range 70-180 mg/dl at 24 hours. Started Feb 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02987738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987738.